Prostate cancer is the leading cause of mortality in men of Western countries. The development of new biosensing devices is expected to improve diagnosis and treatment outcome.
Screening for prostate-specific antigen is the main method for diagnosing prostate cancer but it often leads to over-diagnosis and unnecessary treatment. Novel early biomarkers of prostate cancer that can be integrated with reliable and robust sensing platforms for predicting clinical outcome and treatment response are urgently needed.
Further details: Novel prostate cancer diagnostic devices that can improve treatment